Fraxin

Fraxin is a coumarin glycoside derived primarily from the bark and leaves of Fraxinus (ash tree) species, where it occurs alongside related compounds like fraxetin and esculin. Its primary investigated mechanism involves modulation of pro-inflammatory cytokine signaling, particularly suppression of IL-6, TNF-α, and IL-1β pathways in immune cells.

Origin & History

Fraxin is a coumarin derivative (fraxetin 6-O-glucoside) isolated from plants in the Fraxinus genus, particularly from the leaves of Fraxinus hupehensis and Fraxinus excelsior (ash trees). It is extracted using ethanol or hot water infusion followed by fractionation techniques including silica gel column chromatography, Sephadex LH-20, or preparative HPLC.

Historical & Cultural Context

While Fraxinus species have been analyzed for bioactive potential, the sources do not specify historical or traditional medicinal uses for fraxin itself. Traditional uses of the parent plants are not detailed in the available research.

Health Benefits

• May modulate inflammatory responses - related Fraxinus extracts showed effects on IL-6, TNF-α, and IL-1β secretion in human monocytes/macrophages (in vitro evidence only)
• Potential anti-inflammatory activity - Fraxinus fractions potentially containing fraxin modulated IL-10 receptor expression in immune cells (preliminary in vitro data)
• No human clinical trials have been conducted on pure fraxin
• No specific health benefits have been clinically validated
• Current evidence limited to phytochemical isolation studies

How It Works

Fraxin, as a coumarin glycoside, is believed to interfere with NF-κB signaling cascades, thereby reducing transcription of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in monocytes and macrophages. Fraxinus-derived fractions containing fraxin have also been shown to modulate IL-10 receptor expression, suggesting potential involvement in anti-inflammatory feedback regulation. Additionally, related coumarins in the fraxin class may inhibit cyclooxygenase (COX) enzyme activity, contributing to reduced prostaglandin synthesis, though direct evidence for fraxin itself on COX remains limited.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on fraxin have been identified. Research is limited to phytochemical isolation studies and in vitro experiments using Fraxinus extracts that may contain fraxin, with no PubMed PMIDs available for human trials.

Clinical Summary

Current evidence for fraxin is restricted almost entirely to in vitro studies using human monocyte and macrophage cell lines, with no robust human clinical trials isolating fraxin as a single compound. Fraxinus plant extracts — which contain fraxin alongside other coumarins and iridoids — have demonstrated measurable reductions in IL-6, TNF-α, and IL-1β secretion in cell culture models, but these findings cannot be attributed solely to fraxin. No large-scale randomized controlled trials exist for fraxin supplementation in humans, making quantified therapeutic dosing and efficacy claims premature. The overall evidence level remains preclinical and exploratory, warranting cautious interpretation of any claimed health benefits.

Nutritional Profile

Fraxin (8-glucosyloxy-7-methoxy-2H-1-benzopyran-2-one; CID: 5273569) is a coumarin glycoside compound with molecular formula C16H18O10 and molecular weight of 370.30 g/mol. It is not a macronutrient or conventional food ingredient and contributes negligible caloric value. As a pure phytochemical compound, it contains no protein, fat, or fiber content of nutritional relevance. Bioactive profile: Fraxin is a hydroxylated coumarin (specifically a glucoside of fraxetin) found naturally in the bark and leaves of Fraxinus species (ash trees) at concentrations typically ranging from 0.1–2.5 mg/g dry weight in bark extracts, though this varies considerably by species and extraction method. It also occurs in Dictamnus albus and select Phillyrea species. The compound contains a glucopyranose sugar moiety attached to the coumarin core, contributing to its relative water solubility compared to aglycone coumarins. Bioavailability: Oral bioavailability data for pure fraxin in humans is absent. Based on structural analogy with other coumarin glucosides, intestinal hydrolysis by beta-glucosidases (gut microbiota or brush-border enzymes) may release the aglycone fraxetin, which could be the primary bioactive form absorbed. Lipid solubility is moderate (LogP estimated ~0.8–1.2). No established dietary reference values, RDAs, or tolerable upper intake levels exist for fraxin as it is not classified as a nutrient.

Preparation & Dosage

No clinically studied dosage ranges for fraxin are available as human trials have not been conducted. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Fraxetin, esculetin, euphorbetin, oleoacteoside, ligstroside

Safety & Interactions

Fraxin-specific human safety data is largely absent, as most safety observations come from studies on whole Fraxinus plant extracts rather than isolated fraxin. Coumarins as a class carry a theoretical risk of potentiating anticoagulant medications such as warfarin, and individuals on blood thinners should avoid supplementation without medical supervision. Fraxinus extracts have occasionally been associated with mild gastrointestinal discomfort in sensitive individuals. Safety during pregnancy and lactation has not been established for fraxin or Fraxinus-derived coumarin extracts, and their use should be avoided in these populations until further data is available.